Cliff Asness's INDV Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 304,202 shares of Indivior Pharmaceuticals, Inc. (INDV) worth $9.27 M, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Cliff Asness has maintained this position in INDV for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 367,715 shares. Largest reduction occurred in Q1 2026, reducing 77,960 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Indivior Pharmaceuticals (INDV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Indivior Pharmaceuticals (INDV) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -77,960 | Reduce 20.40% | 304,202 | $30.48 |
| Q4 2025 | +367,715 | Add 2545.27% | 382,162 | $35.88 |
| Q3 2025 | +14,447 | New Buy | 14,447 | $24.11 |
Cliff Asness's Indivior Pharmaceuticals Investment FAQs
Cliff Asness first purchased Indivior Pharmaceuticals, Inc. (INDV) in Q3 2025, acquiring 14,447 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Indivior Pharmaceuticals, Inc. (INDV) for 3 quarters since Q3 2025.
Cliff Asness's largest addition to Indivior Pharmaceuticals, Inc. (INDV) was in Q4 2025, adding 382,162 shares worth $13.71 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 304,202 shares of Indivior Pharmaceuticals, Inc. (INDV), valued at approximately $9.27 M.
As of the Q1 2026 filing, Indivior Pharmaceuticals, Inc. (INDV) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Indivior Pharmaceuticals, Inc. (INDV) was 382,162 shares, as reported at the end of Q4 2025.